Cardiothoracic & vascular anesthesia
Recurrence-free survival after curative resection of non-small cell lung cancer between inhalational gas anesthesia and propofol-based total intravenous anesthesia: a multicenter, randomized, clinical trial (GAS total intravenous anesthesia (TIVA) trial): protocol description
Study context
- Population
- Adults undergoing lung resection surgery with curative intent for non-small cell lung cancer (NSCLC), at 22 international sitesplanned enrollment
- Participants
- 5,384 adults
- Planned comparison
- Propofol-based TIVA vs volatile anaesthetics
- Primary endpoint
- RFS
Methodological detailsprotocol, double-blind, multicentre, pragmatic, 1:1 allocation, Planned 80% power to detect a 3% treatment effect (HR 0.83) at alpha 0.05 for recurrence-free survival (RFS) at 3 years, Secondary outcomes: overall survival and complications within postoperative 7 days
- Protocol
- Double-blind
- Multicentre
- Pragmatic
- 1:1 allocation
- Planned 80% power to detect a 3% treatment effect (HR 0.83) at alpha 0.05 for RFS at 3 years
- Secondary outcomes: overall survival and complications within postoperative 7 days
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Recurrence-free survival after curative resection of non-small cell lung cancer between inhalational gas anesthesia and propofol-based total intravenous anesthesia: a multicenter, randomized, clinical trial (GAS TIVA trial): protocol description. Perioper Med (Lond). Published 23 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →